Mitomycin C, methyl-CCNU and 5-fluorouracil in the treatment of metastatic colorectal carcinoma

1980 ◽  
Vol 5 (1) ◽  
pp. 39-42 ◽  
Author(s):  
Philip D. Bonomi ◽  
Govind Chandra ◽  
Arthur H. Rossof ◽  
David Klaassen
Keyword(s):  
Colorectal Carcinoma ◽  
Mitomycin C ◽  
Metastatic Colorectal Carcinoma

Mitomycin C pharmacokinetics in patients with recurrent or metastatic colorectal carcinoma

1987 ◽  
Vol 65 (3) ◽  
pp. 407-411 ◽  
Author(s):  
Charles Erlichman ◽  
A. Michael Rauth ◽  
Rena Battistella ◽  
Sheldon Fine
Keyword(s):  
Colorectal Carcinoma ◽  
Mitomycin C ◽  
High Performance ◽  
Single Agent ◽  
Area Under The Curve ◽  
Metastatic Colorectal Carcinoma ◽  
Active Metabolites ◽  
Small Component ◽  
Drug Concentrations ◽  
Hplc Technique

The pharmacokinetics of mitomycin C as a single agent have been determined in 25 treatment courses given to 18 patients with recurrent or metastatic colorectal carcinoma using a high performance liquid chromatography (HPLC) assay to analyze plasma and urine samples. The plasma pharmacokinetics conformed to a two-compartment linear model in 21 of 25 courses monitored with a mean t½λ1 of 9.8 ± 1.2 (SEM) min and mean t½λz of 64.1 ± 8.9 (SEM) min. The large variation observed in t½λz was not related to dose or treatment, but an interaction of these two factors approached significance (p = 0.057). Renal excretion in the 12 courses in which it was determined averaged only 2.3% of the total administered dose during the first 4 h monitored and no mitomycin C metabolites were detected in plasma or urine by the HPLC technique used. The most common toxicity, thrombocytopenia, did not correlate with t½λz or the area under the curve. This may be due to (i) a failure to monitor active metabolites of mitomycin C; (ii) other factors besides plasma drug concentrations that mediate toxicity towards marrow elements; or (iii) the small number of courses associated with thrombocytopenia (<100 000/mm3). Our study indicates that (i) an interaction of drug dose and treatment course may be associated with increasing t½λz; (ii) the renal clearance contributes a small component of mitomycin C elimination; (iii) metabolites of mitomycin C cannot be detected by the present HPLC technique; and (iv) routine monitoring of mitomycin C using present methods cannot be recommended for clinical use to predict toxicity.

Hepatic artery infusion with 5-fluorouracil and mitomycin-c in metastatic colorectal carcinoma phase ii study

1982 ◽  
Vol 10 (5) ◽  
pp. 463-470 ◽  
Author(s):  
Asgeir Theodors ◽  
Ronald M. Bukowski ◽  
Ian Lavery ◽  
James S. Hewlett ◽  
Robert B. Livingston ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Mitomycin C ◽  
Hepatic Artery ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Hepatic Artery Infusion ◽  
Metastatic Colorectal Carcinoma

Tc-99m DMSA Uptake by Metastatic Colorectal Carcinoma

2004 ◽  
Vol 29 (8) ◽  
pp. 485-487 ◽  
Author(s):  
Phivi Rondogianni ◽  
George Koniaris
Keyword(s):  
Colorectal Carcinoma ◽  
Metastatic Colorectal Carcinoma

scholarly journals Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study

HPB ◽  
2010 ◽  
Vol 12 (1) ◽  
pp. 31-36 ◽  
Author(s):  
Matthew Bower ◽  
Tiffany Metzger ◽  
Ken Robbins ◽  
Dana Tomalty ◽  
Vlatimil Válek ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Colorectal Carcinoma ◽  
Metastatic Colorectal Carcinoma ◽  
Drug Eluting Beads ◽  
Drug Eluting
Sign in / Sign up

Export Citation Format

Share Document